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Background and purpose — Long-term survivors of cancer can 
develop adverse effects of the treatment. 60% of cancer patients 
survive for at least 5 years after diagnosis. Pelvic irradiation can 
cause bone damage in these long-term survivors, with increased 
risk of fracture and degeneration of the hip. 
Patients and methods — Analyses were based on linkage 
between the Cancer Registry of Norway (CRN) and the Nor-
wegian Arthroplasty Register (NAR). All women who had been 
exposed to radiation for curative radiotherapy of gynecological 
cancer (40–60 Gy for at least 28 days) were identified in the CRN. 
Radiotherapy had been given between 1998 and 2006 and only 
patients who were irradiated within 6 months of diagnosis were 
included. The control group contained women with breast cancer 
who had also undergone radiotherapy, but not to the pelvic area. 
Fine and Gray competing-risk analysis was used to calculate 
subhazard-rate ratios (subHRRs) and cumulative incidence func-
tions (CIFs) for the risk of having a prosthesis accounting for dif-
ferences in mortality.
Results — Of 962 eligible patients with gynecological cancer, 26 
(3%) had received a total hip replacement. In the control group 
without exposure, 253 (3%) of 7,545 patients with breast cancer 
had undergone total hip replacement. The 8-year CIF for receiv-
ing a total hip replacement was 2.7% (95% CI: 2.6–2.8) for gyne-
cological cancer patients and 3.0% (95% CI: 2.95–3.03) for breast 
cancer patients; subHRR was 0.80 (95% CI: 0.53–1.22; p = 0.3). 
In both groups, the most common reason for hip replacement was 
idiopathic osteoarthritis.
Interpretation — We did not find any statistically significantly 
higher risk of undergoing total hip replacement in patients with 
gynecological cancer who had had pelvic radiotherapy than in 
women with breast cancer who had not had pelvic radiotherapy.

After approximately 5 years, two-thirds of cancer patients are 
still alive (Sant et al. 2009). Research on late adverse effects 
in cancer survivors has gained increasing interest over the last 
decade. However, the main interest has been on secondary 
cancer events (Curtis et al. 2006), cardiovascular complica-
tions, and emotional problems (Meyerowitz et al. 2008). The 
relationship between cancer, skeletal disorders, and treatment 
has rarely been investigated. Skeletal adverse effects of irra-
diation include cell death, cellular injury, and abnormal bone 
repair—although the underlying mechanisms are not fully 
understood (Yurut-Caloglu et al. 2010).
Pelvic insufficiency fractures may be one of the possible late 
side effects of radiotherapy to the pelvic area. The incidence of 
such fractures has been reported to be 5–20% in gynecological 
cancer patients who have undergone radiotherapy (Kwon et al. 
2008, Oh et al. 2008, Schmeler et al. 2010, Shih et al. 2013). 
Less common effects of pelvic irradiation include acetabular 
protrusion and avascular necrosis of the femoral head (Fiorino 
et al. 2009). Other studies have not found any increased risk 
of hip fracture after pelvic irradiation (Feltl et al. 2006, Elliott 
et al. 2011). We wanted to examine the risk of receiving a total 
hip replacement in patients with cancer in the pelvic area who 
had undergone radiotherapy compared to patients with cancer 
at another location who had not undergone pelvic irradiation. 
Our hypothesis was that patients who have had high-dose 
pelvic radiotherapy would have a higher risk of undergoing 
total hip replacement than women who have had radiotherapy 
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Patients and methods
Study population
Since 1953, it has been compulsory to register all new cancer 
cases in the Cancer Registry of Norway (CRN). The CRN 
has records on 99% of all cancer patients in Norway (Cancer 
Registry of Norway 2012). This includes information on 
each cancer episode for each patient regarding type of malig-
nancy, date of diagnosis, initial treatment, and demographics. 
In 1998, the CRN started a national sub-register containing 
information about radiation therapy given to cancer patients. 
For each irradiated patient, this register contains information 
on target field and dose, fractionation pattern, and start and 
end of treatments.
The Norwegian Arthroplasty Register (NAR) has been col-
lecting information on total hip arthroplasty in Norway since 
September 1987. This voluntary register has a compliance rate 
exceeding 95% (Espehaug et al. 2006). For each patient, the 
NAR has information on each implant operation regarding 
diagnosis, date of operation, and brand of implant (Norwegian 
Arthroplasty Register 2013). 
Data on total hip replacement were linked to the cancer 
patients using the 11-digit unique personal identification 
number assigned to each inhabitant of Norway. Cancer 
patients, all registered total hip replacements, and the date 
of death for each patient were linked. Then we identified a 
subgroup consisting of women who had undergone pelvic 
curative external beam radiotherapy (EBRT) for gynecologi-
cal cancer and a group without such exposure, represented by 
female breast cancer patients who had undergone irradiation 
(40–60 Gy) to the breast area but not to the pelvic area. In 
the group with pelvic exposure, we identified 568 patients 
with cervical cancer, 382 patients with endometrial cancer, 10 
patients with ovarian cancer, and 2 patients with vaginal and 
external genital cancer. 
All curative series of pelvic EBRT included in this study 
were given between 1998 and 2006 (Table 1). Only patients 
who started this radiotherapy within 6 months of diagno-
sis were included. Furthermore, we restricted the inclusion 
to patients with target doses of 40–60 Gy to the pelvic area 
provided over at least 28 days. A radiation dose plan for one 
patient with cervical cancer is given in Figure 1. The dose 
distribution of any brachytherapy was not accounted for. The 
group without pelvic exposure was defined by a similar link-
age between the CRN and NAR, identifying patients who had 
undergone curative radiotherapy for breast cancer. 
Any patients who had undergone total hip replacement prior 
to radiation therapy were excluded. 8,507 cancer patients (962 
with pelvic exposure and 7,545 without pelvic exposure) were 
included in the study.
Statistics
We used Cox proportional hazards regression models to cal-
culate hazard rate ratios (HRRs) between the pelvic exposure 
group and the group without pelvic exposure. Because of a 
substantial difference in mortality between the 2 cancer patient 
groups, we also calculated sub-hazard rate ratios (subHRRs) 
using a Fine and Gray regression model, to account for the 
competing risks between receiving a total hip prosthesis and 
death (Fine and Gray 1999). The sub-hazard is based on the log 
of the cumulative incidence function (CIF). From the Fine and 
Gray model, we also present the estimated CIF for receiving a 
total hip prosthesis. 
The observation time was from the patient’s first cancer 
diagnosis until total hip replacement, death, or the end of the 
study on December 31, 2010, whichever came first.
Figure 1. Dose distribution from radiotherapy of a cervical cancer 
patient. The yellow, light blue, and purple lines represent the 50-Gy, 
45-Gy, and 25-Gy isodoses, repectively. The 4 radiation fields applied 
in patients with cervical cancer encompass the whole pelvis, the distal 
border of the fields being 0–10 mm below the obturator foramen. 
Depending on the radiotherapy technique used, the acetabula receive 
30–50 Gy while the lateral parts of the hip are irradiated with 10–30 Gy.
Table 1. Patient numbers and numbers of total hip replacements (THRs) by year of therapy
 1997–1998 1999–2000 2001–2002 2003–2004 2005–2006 Total
      
Breast cancer      
  Total number of patients 1,087 1,292 1,760 2,080 1,326 7,545
  Number of THRs 35 65 65 58 30 253
Gynecological cancer      
  Total number of patients 81 229 236 254 162 962
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We used the statistical software package IBM SPSS Sta-
tistics version 21.0 for Windows, and the cmprsk library in 
the statistical package R, version 3.0.0 (http://www.R-project.
org). Any p-values less than 0.05 were considered statistically 
significant.
Results
We identified 962 gynecological cancer patients who had 
undergone pelvic irradiation therapy (568 cervical cancer, 
382 endometrial cancer, 10 ovarian cancer, and 2 vaginal and 
external genital cancer) and 7,545 breast cancer patients with-
out any pelvic exposure. The mean age at primary diagnosis 
of gynecological cancer was 58 (SD 14) years, while the cor-
responding mean age in breast cancer patients was 56 (SD 
11) years (Table 2). The mean difference in age was 2.4 years 
(CI: 1.4–3.3; p < 0.001). Gynecological cancer patients had a 
median follow-up of 7.0 years, while for breast cancer patients 
median follow-up was 8.1 years. 
26 women with gynecological cancer and 253 women with 
breast cancer received a primary total hip replacement after 
the date of primary diagnosis of cancer. The most common 
reason for undergoing a total hip replacement was idiopathic 
osteoarthritis, which was observed in 19 gynecological cancer 
patients (73%) and 192 breast cancer patients (76%). Other 
reasons for total hip replacement were fracture of the femoral 
neck in 1 gynecological cancer patient and in 24 breast cancer 
patients. Hip replacement because of congenital dysplasia 
was found in 2 gynecological patients and 17 breast cancer 
patients. 
Of the 26 patients with gynecological cancer and total hip 
replacement, 2 (8%) had since been revised and 5 (19%) had 
received a primary total hip replacement in the other hip. Of 
253 patients with breast cancer and total hip replacement, 6 
(2%) had been revised and 42 (17%) had received a primary 
total hip replacement in the second hip. All patients with total 
hip replacement were alive at the end of the study (December 
31, 2010).
There were 305 deaths in the gynecological cancer patients 
(32%) and there were 1,052 deaths in the breast cancer patients 
(14%).
Based on the Fine and Gray method, for gynecological 
cancer patients the risk (cumulative incidence function) of 
receiving a prosthesis after 5 years was 1.35% (CI: 1.28–1.43) 
and after 8 years was 2.72% (CI: 2.61–2.82). The correspond-
ing percentages for patients with breast cancer were 1.77% 
(CI: 1.74–1.80) and 2.99% (CI: 2.95–3.03) (Table 2 and 
Figure 2).
From the Cox proportional hazards regression, with the 
endpoint total hip replacement and breast cancer patients as 
reference, we found a hazard rate ratio (HRR) of 0.79 (CI: 
0.53–1.20; p = 0.27) for undergoing hip replacement in the 
gynecological cancer patients (relative to the breast cancer 
patients). Using the Fine and Gray competing-risk model, 
adjusting for death as the competing endpoint and with breast 
cancer patients as the reference category, we found a sub-haz-
ard rate ratio of 0.80 (CI: 0.53–1.22; p = 0.30) for a total hip 
replacement in gynecological cancer patients (Table 2). 
 
Discussion
Radiation therapy directed at the pelvic region may damage 
bone structures or bone repair in the hip (Fu et al. 1994), 
Table 2. Numbers of cancer patients and of cancer patients who received a total hip replacement (THR), and risk estimates from a Cox 
model and a Fine and Gray model
  Cox Fine and Gray
 n THR FU a Age HRR p-value subHRR p-value 5-year CIF b 8-year CIF b
    mean (SD) (95% CI)  (95% CI)  (95% CI) (95% CI)
            
Gynecological cancer 962  26 7.0 58 (14)  0.79 (0.53–1.20) 0.3 0.80 (0.53–1.22) 0.3 1.35 (1.28–1.43) 2.72 (2.61–2.82)
Breast cancer 7,542 253 8.1 56 (11) 1 (ref) – 1 (ref) – 1.77 (1.74–1.80) 2.99 (2.95–3.03)
           
a FU: follow-up, median years. 





Figure 2. Risk of receiving a total hip replacement, calculated based on 
cumulative incidence function from the Fine and Gray competing-risk 
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through an imbalance of—or reduced activity in—osteoclasts 
and osteoblasts. Based on bone scan images, osteoblast activ-
ity within a radiation field is reduced for several years after 
radiotherapy (Fossa and Winderen 1993). Radiation therapy 
could also cause periarticular fibrosis and increased cartilage 
degeneration, which might result in a hip replacement (Aigner 
et al. 2002, Hong et al. 2010). However, our main hypothesis 
of increased need of total hip replacement after pelvic radio-
therapy was not supported when we compared such patients 
with a group of cancer patients who had not undergone pelvic 
radiotherapy.
In an earlier study, we found that cancer patients had a higher 
risk of receiving a total hip replacement than the Norwegian 
population as a whole (Dybvik et al. 2009). In that study, the 
type of treatment was not considered. We have found very few 
studies on hip arthroplasty after radiation therapy (Kim et al. 
2007, Demircay et al. 2009). However, several studies have 
dealt with fractures in the hip region after pelvic radiotherapy. 
1 study showed increased risk of pelvic fractures after pelvic 
irradiation in older women (Baxter et al. 2005), there has been 
1 study on groin irradiation (Grigsby et al. 1995), and some 
case reports on pelvic irradiation (Epps et al. 2004, Ayorinde 
and Okolo 2009) found femoral neck fracture to be a com-
plication. Other authors have reported femoral head necrosis 
after irradiation (Hanif et al. 1993, Abdulkareem 2013). 
Our control group of women without pelvic exposure was 
selected for maximal age-related compatibility with the study 
group. Since the 1990s, curative treatment of breast cancer 
patients has not included pelvic radiotherapy, although some 
of them may subsequently have received low-dose palliative 
pelvic radiotherapy. Additionally, hormone treatment with 
Tamoxifen was standard in women with breast cancer in 
Norway during the timespan of our study. This treatment may 
prevent osteoporosis (Becker et al. 2012), which would reduce 
the risk of receiving a hip replacement.
1 study found pelvic insufficiency fractures to be uncom-
mon complications in irradiated patients with gynecological 
cancer (Huh et al. 2002), while other studies have found fre-
quent pelvic insufficiency fractures in women after radiation 
therapy (Abe et al. 1992, Blomlie et al. 1996, Kwon et al. 
2008), including acetabulum insufficiency fractures (Ikushima 
et al. 2006, Schmeler et al. 2010). None of the patients with 
gynecological cancer in our study who later received a pros-
thesis had fracture (or fracture sequelae) registered as the 
reason for their prosthesis.
The indication for a hip replacement results from a balance 
between the severity of the hip disease and the general health 
of the patient. A total hip replacement is a major operation that 
is generally reserved for healthier patients (Lie et al. 2000). If 
gynecological cancer patients have more severe comorbidity 
than breast cancer patients, this could lead to bias related to 
receiving a hip replacement for the 2 cancer types. 
Survival in the breast cancer patients and the gynecologi-
cal cancer patients showed considerable differences. Patient 
mortality must therefore be taken into account in analysis of 
the risk of receiving a total hip replacement. This was done 
using competing-risk analysis according to Fine and Gray 
(1999), comparing sub hazards. Competing-risk models have 
become increasingly recognized as an important tool in sur-
vival and event history analyses where there can be more than 
one outcome and the occurrence of the other events may alter 
the risk of the event of interest. For clinical outcomes such 
as, for example, a total hip replacement or its revision, death 
may be a substantial competing outcome that should be taken 
into consideration in the analysis (Gillam et al. 2010,  2011). 
Since mortality in the gynecological cancer patients was much 
higher than in the breast cancer patients (32% as opposed to 
14%), Kaplan-Meier curves might give biased results. Fur-
thermore, since the competing-risk model compares the risks 
of receiving a hip replacement, it should be favored over the 
Cox model, even though they did not lead to different conclu-
sions in the present study. 
This study had some limitations. A total hip replacement is a 
clear-cut endpoint, but it may not be ideal since patients whose 
hips have failed—but who do not receive a hip replacement—
will not be included. A hip fracture could be a more sensitive 
measure of a diseased hip (Gjertsen et al. 2008)—or alterna-
tively, patient-reported measures of hip pain (Waldenström et 
al. 2012) or radiographic examination of all patients to disclose 
joint diseases. The use of breast cancer patients as a compari-
son group for the gynecological cancer patient group might 
also be questioned. Ideally, we would like to have compared 2 
cancer types with the same etiology, the only difference being 
the area/location of the irradiation. Using the competing-risk 
approach, we adjusted for the difference in mortality. However, 
other etiological factors may contribute to the difference in risk 
of receiving hip replacement in breast cancer and gynecologi-
cal cancer patients. Measures of general health and health at 
the time of receiving THR (e.g. ASA class) and quality of life 
(e.g. EQ5D) could be factors on the pathway from cancer to the 
risk of receiving a THR. Such data were not available. Finally, 
even though this was an observational study based on 2 large 
national databases, the number of gynecological cancers with 
curative radiation therapy was limited. 
Based on our findings, we conclude that curative pelvic 
radiotherapy in gynecological cancer patients does not increase 
the risk of receiving a total hip arthroplasty compared to breast 
cancer patients who do not undergo pelvic radiotherapy. 
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